Concept Award – HT942526KCRPCA
- Letters of Intent due 14 July 2026
- Up to USD$120,000 for 1 year
- Supports highly innovative, untested, potentially ground-breaking concepts in kidney cancer.
- Clinical trials not allowed
- Preliminary data not allowed
- Must address one or more of the Focus Areas
- Apply here
- Document – Program Announcement – HT942526KCRPCA_GG
Idea Development Award – HT942526KCRPIDA
- Letters of Intent due 14 September 2026
- Up to USD$900,000 (Single PI) or Up to USD$1.2M (Partnering PI Option) over 3 years
- Supports the development of innovative, high-impact ideas that advance the understanding of kidney cancer and ultimately lead to improved patient outcomes.
- PIs must be at level of Assistant Professor or equivalent
- Clinical trials not allowed
- Preliminary data required. (does not need to derive exclusively from kidney cancer research)
- Must address one or more of the Focus Areas
- Apply here
- Document – Program Announcement – HT942526KCRPIDA_GG
Academy of Kidney Cancer Investigators – Early-Career Scholar Award – HT942526KCRPAKCIECSA
- Letters of Intent due 14 September 2026
- Up to USD$1.2M over 4 years
- Supports impactful kidney cancer research and the addition of new Early-Career Scholars (ECS) to a virtual academy, providing intensive mentoring, national networking, research collaborations and a peer group for early-career kidney cancer investigators.
- Investigators must be within 7 years of last postdoctoral research position (PhD), clinical fellowship (MD), or equivalent
- Investigators need not work or practice at an academic institution
- ECSs whose ability to commit to conducting kidney cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.
- Applications must identify a designated mentor who is an experienced kidney cancer investigator or clinician with a record of kidney cancer publications or funding.
- A designated mentor may only mentor one scholar.
- The designated mentor and the scholar may work or practice at different institutions.
- Clinical trials not allowed
- Preliminary data required
- Must address one or more of the Focus Areas
- Apply here
- Document – Program Announcement – HT942526KCRPAKCIECSA_GG
Focus Areas
- Conduct basic biology research to better understand etiology and cancer progression, metastatic disease, refractory disease and therapeutic resistance, genetic and environmental risk factors, and the prevention of kidney cancer
- Identify and develop new strategies for screening, early-stage detection, and accurate diagnosis and prognosis prediction of kidney cancers, including biomarkers and imaging and treatment of early-stage cancers
- Define the biology of rare kidney cancers and develop treatments to improve outcomes and reduce death
- Develop novel, less toxic therapeutic strategies for all types of kidney cancer
- Identify and implement strategies to improve quality of life and survivorship for kidney cancer patients
- Identify and implement strategies to enhance outcomes in high-risk kidney cancer patients, including those with exposure to environmental factors and inherent genetic or biological factors
- Increase capacity and multi-disciplinary research to transform kidney cancer patient care
